Background Image

Meet Remedium Bio

The people who believe that any disease can be cured

Explore how

Learn more about us

  • History

    Remedium is a biotechnology company focused on the development of treatments for large unmet clinical needs. To enable this, we developed a revolutionary gene therapy platform, which enables safe, effective, and durable delivery of therapeutic genes while allowing for simple post-treatment dose adjustment. The Prometheus™ adjustable gene therapy platform enables replacement of a broad range of subcutaneously administered protein treatments with a single injection, adjustable dose gene therapy. The system has an exceptionally high degree of specificity and remains localized to the site of the subcutaneous injection, offering a safe and durable, single injection alternative, at a fraction of the current protein-based therapeutic treatment cost. Remedium’s pipeline includes several disease modifying treatments with unprecedented efficacy in the fields of endocrinology (weight loss and type 2 diabetes), immunology, neurology, and musculoskeletal diseases.

  • Vision

    Our Vision at Remedium is very simple: We firmly believe that any disease can be cured. This vision creates a fundamental understanding and allows us to approach any therapy like a simple problem: 1) identify the root cause, 2) determine the most optimal treatment approach, 3) validate the treatment approach. Our vision enables us with the drive and motivation, while our systematic approach enables us with the tools to bring new treatments to patients.

  • Culture

    We strive to achieve a corporate culture that is grounded in our belief that every opinion is valuable, every human being is highly capable, and every life is sacred. Derived from this, our culture is grounded in 5 core fundamentals: 1) Collaborative Innovation, 2) Integrity and Transparency, 3) Mutual Respect, 4) Unquenchable Thirst for Finding Cures, 5) Diligent Drive and Execution.

Background

Working toward the cure is in our DNA,
a brilliant today for a brighter tomorrow.

Remedium bio corporate video

News and Investor Information

news

Meet the Remedium Team

The people who believe that any disease can be cured.

  • Executive Team
    Pic
    President and CEO

    Frank Luppino

    Frank Luppino is the President and CEO of Remedium Bio, also serving as the Chairman of the Board of Directors. Prior to joining Remedium Frank's successful track record includes the development, industrialization, and commercial launch of a broad array of products including Cell Therapies for wound and cartilage repair, anti-inflammatory and analgesic Drug-Device combination products in orthopedics and aesthetic medical markets, as well as biologic macromolecules for the prevention of surgical adhesions.

    Prior to joining Remedium, Frank served in a series of executive roles including as the CEO of Biosource CXO, Chief Operating Officer of Anika Therapeutics, Vice President of Operations at Bionostics, and various roles of increasing responsibility at Raytheon and Black & Veatch. Frank holds a Bachelor of Science from Lehigh University. 


    Pic
    Chief Business Officer

    James Carroll

    James Carroll is the Chief Business Officer at Remedium Bio. Prior to Remedium, James held roles of increasing responsibilities at companies including ExonanoRNA, Bionostics, Biovest International, Squadra Investments, Repligen, Millipore, Waters, and Bio-Rad for over 20 years. In addition, James has an extensive background in early Life Science company fundraising and investment including as a Founder and General Partner at Boston Life Science Investments and Managing Director of Wharton Alumni Angels for Life Science Investments.

    James has significant experience with corporate acquisitions, mergers, and divestitures, holding advanced business certifications and alumni status from MIT Sloan, Harvard, and Wharton and with an initial degree in Organic Chemistry and an MBA from Northeastern University.


    Pic
    Chief Operating Officer

    Alex Goraltchouk

    Alex Goraltchouk is the Chief Operating Officer at Remedium Bio. Alex has extensive background developing and industrializing biologics, small molecules, as well as gene and cell therapy products at companies including Allergan, Regeneron, and Biogen. Prior to Remedium, Alex held several executive roles at public and private companies leading the development and industrialization of clinical and commercial products in the Endocrinology, Rheumatology, and Cardiology space.

    Alex holds a Bachelor in Materials Engineering and Master in Chemical Engineering from the University of Toronto, an MBA and Master of Science in Finance from Indiana University, and a Master of Microbiology and Cell Sciences from the University of Florida. He is a Cornell Certified Six Sigma Black Belt, holds an MIT MicroMasters in Supply Chain Management, and a PMP certification from the Project Management Institute.


    Pic
    Vice President, R&D

    Dr. Alexey Seregin

    Dr. Alexey Seregin is the Vice President, Research and Development at Remedium Bio. Alexey has extensive background innovating and advancing to the clinic viral and non-viral gene therapies in several therapeutic areas including neurodegenerative, neuromuscular, hematologic, metabolic, and gastrointestinal disorders. Before joining Remedium, Alexey led high-priority R&D programs at organizations ranging from start-up to Fortune 500, such as Takeda, Biogen, Bioverativ, and Solid Biosciences.

    Dr. Seregin holds PhD from The University of Texas Medical Branch at Galveston and is an inventor on a number of issued patents and patent applications covering the development of novel viral and non-viral vector technologies for a broad range of therapeutic indications. Dr. Seregin is a recognized authority in the field of genetic engineering and gene delivery, bringing over 15 years industrial and academic experience to Remedium, and having published in an extensive number of high-impact peer-reviewed journals.


  • Advisors
    Pic
    Scientific Advisor Rheumatology

    Dr. Timothy McAlindon, MD, MPH

    Dr. McAlindon is the Chief of the Division of Rheumatology at the Tufts Medical Center and Professor of Medicine at Tufts University School of Medicine. Dr. McAlindon is a renowned authority in Rheumatology, having led the American College of Rheumatology (ACR) Rheumatoid Arthritis (RA) Clinical Treatment Guideline Literature Review Team and chaired the Osteoarthritis Research Society International (OARSI) Treatment Guideline Development Committee. Dr. McAlindon received his Doctorate in Medicine and Bachelor of Medicine from the University of Southampton Medical School, his MPH from Boston University School of Public Health, and completed medical training at the Bristol Royal Infirmary, and St. Thomas' Hospital in London in the UK.


    Pic
    Scientific Advisor Endocrinology

    Dr. Anastassios Pittas, MD, MS

    Dr. Pittas is the Chief of the Division of Endocrinology, Diabetes, and Metabolism; Co-Director, Diabetes and Lipid Center, Professor of Medicine at Tufts University School of Medicine and Adjunct Professor of Nutrition and Policy at Tufts University Friedman School of Nutrition, Science and Policy. Dr. Pittas serves as the Associate Director of the Endocrinology Fellowship Program and co-Director of the Diabetes Clinic. From 2000 to 2008, he served as the Director of the Endocrine Pathophysiology course at Tufts University School of Medicine. Dr. Pittas holds a Bachelor of Science in Biology from MIT, a Master of Science in Clinical Research from the Sackler School of Biomedical Sciences at Tufts University, an MD from the Weill Medical College of Cornell University, completed his Internal Medicine Residences at the New York Presbyterian Hospital, and a Fellowship in Endocrinology, Diabetes, and Metabolism at the Tufts Medical Center.


    Pic
    Corporate Advisor

    Dr. Charles Sherwood, PhD

    Dr. Sherwood is the Founder of Sherwood Ventures, a biotech-focused early stage Venture Capital firm, and formerly the President and CEO of Anika Therapeutics, a global public-market rheumatology-focused specialty pharmaceuticals company. Prior to Anika, Dr. Sherwood held roles of increasing responsibilities at companies including J&J and Chiron. Holding a Bachelor of Science in Chemical Engineering from Cornell and a Ph.D. in Polymer Science and Engineering from the University of Massachusetts, Boston, Dr. Sherwood brings over five decades of rheumatology and osteoarthritis experience to Remedium Bio. Dr. Sherwood led the development, industrialization, clinical trials, and commercial launch of a number of currently market-leading palliative OA therapies including Monovisc®, Orthovisc®, and Cingal®; as well as a first-in-class cell therapy HyalograftC® and EU-market leading single step focal cartilage lesion repair product Hyalofast®.


    Pic
    Scientific Advisor Rheumatology

    Prof. Li Zeng, BA, MS, MA, PhD

    Dr. Zeng is the Associate Professor of Immunology at the Graduate School of Biomedical Sciences at Tufts University and a renowned authority in Osteoarthritis research. Dr. Zeng holds an MA and PhD in Cell & Molecular Biophysics from Columbia University, an MS in Biochemistry from Tsinghua University, and a BA in Plant Physiology & Biochemistry from Beijing Agricultural University. Dr. Zeng manages a research laboratory at Tufts University conducting rheumatology research focused on the understanding of cartilage development in vertebrate embryos, molecular mechanisms involved in cell fate determination during cartilage formation and patterning, as well as cartilage-related defects, arthritis, and cartilage repair.


    Pic
    Scientific Advisor Rheumatology

    Dr. Jeff Ellsworth, PhD

    Dr. Ellsworth is a renowned authority on the FGF18 protein and its applications in the treatment of Osteoarthritis and Stroke, having led the R&D team that originally discovered FGF18’s ability to regenerate cartilage. Dr. Ellsworth holds a PhD in Pharmacology and Cell Biophysics from the University of Cincinnati College of Medicine and a Bachelor of Science in Chemistry from the Indiana University Bloomington. Upon completion of his dissertation defense, Dr. Ellsworth spent a number of years as a post-doctoral fellow at Stanford University School of Medicine researching lipoprotein receptors and lipid metabolism. Dr. Ellsworth has held roles of increasing responsibilities at CV Therapeutics, ZymoGenetics, Moderna, and Homology Medicines and is currently the CSO at the cardiac regeneration company Recardia Therapeutics, Inc.


  • Board
    Pic
    Chairman of the board

    Frank Luppino

    Frank Luppino is the President and CEO of Remedium Bio, also serving as the Chairman of the Board of Directors. Prior to joining Remedium Frank's successful track record includes the development, industrialization, and commercial launch of a broad array of products including Cell Therapies for wound and cartilage repair, anti-inflammatory and analgesic Drug-Device combination products in orthopedics and aesthetic medical markets, as well as biologic macromolecules for the prevention of surgical adhesions.

    Prior to joining Remedium, Frank served in a series of executive roles including as the CEO of Biosource CXO, Chief Operating Officer of Anika Therapeutics, Vice President of Operations at Bionostics, and various roles of increasing responsibility at Raytheon and Black & Veatch. Frank holds a Bachelor of Science from Lehigh University. 


    Pic
    Board member

    Richard Hague

    Richard is an accomplished biotechnology executive and board member with extensive experience in the development and commercialization of innovative therapies focused mainly on the orthopedic and wound care markets. Richard is currently the President and CEO of PolarityTE, a regenerative medicine company developing its lead autologous cell based product for skin regeneration.

    Before joining PolarityTE, Richard held executive roles with several leading healthcare companies, which included Genzyme and later Sanofi (post Sanofi's acquisition of Genzyme) where he was VP/General Manager of the company’s Cell Therapy and Regenerative Medicine Business Unit. While at Genzyme, Richard was involved in the launch of the first autologous cell therapy for cartilage repair and the first HA injectable for the management of osteoarthritis pain. Richard’s broad experience includes raising capital in the public markets, licensing and M&A transactions, and successful product launches via the CBER and CDRH regulatory pathways. Richard is a graduate of the University of Connecticut’s School of Business.


    Pic
    Board member

    Alex Goraltchouk

    Alex Goraltchouk is the Chief Operating Officer at Remedium Bio. Alex has extensive background developing and industrializing biologics, small molecules, as well as gene and cell therapy products at companies including Allergan, Regeneron, and Biogen. Prior to Remedium, Alex held several executive roles at public and private companies leading the development and industrialization of clinical and commercial products in the Endocrinology, Rheumatology, and Cardiology space.

    Alex holds a Bachelor in Materials Engineering and Master in Chemical Engineering from the University of Toronto, an MBA and Master of Science in Finance from Indiana University, and a Master of Microbiology and Cell Sciences from the University of Florida. He is a Cornell Certified Six Sigma Black Belt, holds an MIT MicroMasters in Supply Chain Management, and a PMP certification from the Project Management Institute.


investor faq

  • what we do
    Remedium bio at a glance

    Remedium Bio, Inc. is a biotechnology company focused on the development of curative therapies for a broad range of pathologies. Our people passionately believe that any disease can be cured and are tirelessly working to deliver therapies to patients for a broad range of therapeutic categories. Grounded in our premise, Remedium scientists discover and develop therapies by appropriately matching treatment modalities with specific disease pathophysiology to replace or augment missing, degenerated, or damaged tissues one treatment at a time.

    Our team is located in the Boston area, a modern-day Mecca of Biotechnology. We are founded on the vision of changing lives via curative breakthroughs with a firm scientific foundation with the goal of creating a company that changes the way we think about treating disease.

  • our people
    our people - the remedium team

    Our people are at the core of everything we do, they are what makes Remedium special, what makes our innovations unique, the driving force behind our vision that any disease can be cured. With this in mind, Remedium strives to hire the most talented professionals in the industry, the brightest minds with the most open hearts - adventurers with an inner child, glass half full, looking at the world through rose colored glasses.

    As a company we firmly believe in diligently and persistently investing in our people, supporting training, education, and growth, every step of their way. Inclusion and diversity are at our core, acceptance of all cultures and ideas is the Remedium gold standard, and it is upon this edifice that we venture to build a company to cure one disease at a time - a brilliant today for a better tomorrow.

  • our science
    the ideas that drive our therapies

    Science is at the foundation of everything we do at Remedium - a uniting principle that innovation, data-driven analysis, and a culture conducive to open discussion that promotes a healthy debate is essential to ideation and delivery of the ideas as treatments to patients. At the core of our values are the principles that all decisions should be supported by data, all scientific ideas are worthy of careful consideration, and turning ideas into medicine is the most noble pursuit of humanity.

  • ethical commitment
    A HIGH ETHICAL AND SOCIAL BAr

    At Remedium, we are firmly committed to upholding the highest ethical standards including integrity, honesty and truthfulness, multicultural and intellectual diversity, respect for all ideas and individuality, inclusion, transparency, freedom of expression, and respect for the dignity and rights of all individuals. Furthermore, we strive to achieve the highest standards in Corporate Social Responsibility and create a sustainable future for our People, Community, and Environment.

    Remedium and our highly-valued team strives to exercise this commitment in everything we do. As members of the Biotechnology community we feel a heightened need to hold ourselves to the highest standards of ethical responsibility in addition to fully abiding by international, federal, and state laws and regulations, following internal policies and industry best practices wherever and whenever possible.

Remedium's current investors

Get In Touch

We are always interested in starting a new conversation and are looking forward to hearing from you. Thank you in advance for your inquiry and please have a wonderful day!


1116 Great Plain Ave, Suite 203
Needham, MA
02492


E: info@remedium-bio.com
P: +1 (978) 467 5217